Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't

Morris Shannon exercised and immediately sold 20,000 ERAS shares for roughly $301,000 at a $15.04 weighted average price, reducing his direct common-stock holdings to zero. He still holds rights to acquire up to 515,800 shares via options, so his economic exposure remains option-heavy. Company metrics: price $15.15 (Mar 26, 2026), market cap ~$4.71B, TTM net loss $127.69M, 1-year price change +924%.

Analysis

This insider sale is information-light as a signal of conviction change but it exposes a subtle but actionable supply/dilution dynamic: outstanding exercisable options are non-trivial relative to tradable float and will only become marketable on vesting/exercise or company buybacks. That creates a schedule-risk where clustered option monetizations (or a need to finance development) can add episodic sell pressure independent of clinical outcomes, compressing near-term multiples for similarly positioned small-cap oncology names.

Second-order competitive effects matter more than the headline sale. Positive trial data from the company’s lead programs would likely trigger rapid strategic interest from large-cap pharm (M&A or licensing), compressing time-to-revenue risk and re-rating the share; conversely, a binary clinical failure could force rapidly dilutive financing because of the company’s pathway-specific R&D cadence, amplifying downside versus peers with later-stage, revenue-generating franchises.

From a risk-timing perspective, treat this name as binary over the next 3–12 months around trial readouts and as a volatility play over 12–36 months for strategic optionality. The proper framing is therefore asymmetric: small, financed option exposure to capture upside from positive readouts or partnership activity, while hedging sizable tail risk from negative clinical/regulatory outcomes or opportunistic dilution.

Behavioral/market micro points: prearranged insider programs reduce informational value of single transactions, but they also reveal management liquidity windows—use those windows to map likely future sell cadence and size your position so that forced selling events (company-wide exercises, fiscal-year tax sells) don’t coincide with your entry or key data events.

Key Decisions for Investors

• Long-dated call LEAP: Buy ERAS Jan‑2028 LEAP calls (target strike ~$20) sized to risk no more than 1–2% of portfolio. Rationale: captures multi-year upside from successful readouts or strategic deal flow; downside limited to premium, target 2–4x payoff if company secures partnership or positive pivotal signals within 12–24 months.
• Hedged equity starter: Buy ERAS shares and simultaneously purchase a 9‑month put ~20% OTM (cost‑effective collar). Rationale: participate in upside into next 3–12 month catalyst window while capping intermediate downside; ideal if you want delta exposure but limit single-event binary risk.
• Volatility calendar: Sell 1–3 month ATM calls or straddles into non‑catalyst windows and use proceeds to buy 12–18 month ATM calls (calendar spread). Rationale: monetize near-term term‑premium and fund long dated optionality; risk is short early vol into an unexpected readout — cap position size and avoid within 2–3 weeks of scheduled releases.
• Pair trade to isolate idiosyncratic upside: Go long ERAS equity (smaller size) and short equal‑dollar XBI (or a small‑cap oncology basket) for 3–12 months. Rationale: isolates company‑specific clinical/partnership upside versus sector moves; reward if ERAS shows relative clinical progress, risk if sector moves strongly on broader biotech flows.